Xiaozhong Z. Chen
38 Guangji Road
Hangzhou, 310022, China
Hangzhou, 310022, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 62 publications
Risk stratification of advanced extranodal extension in retropharyngeal lymph nodes for nasopharyngeal carcinoma: a multi-center study.
Journal: Cancer imaging : the official publication of the International Cancer Imaging Society
Published: April 19, 2026
Comparison of the eighth and ninth editions of American Joint Committee on Cancer/Union for International Cancer Control staging for non-metastatic nasopharyngeal carcinoma.
Journal: Otolaryngologia polska = The Polish otolaryngology
Published: March 23, 2026
Randomized, multicenter phase 3 study evaluating radiotherapy versus concurrent chemoradiotherapy in nasopharyngeal carcinoma patients achieving CR/PR after induction chemotherapy.
Journal: BMC medicine
Published: March 21, 2026
Becotatug vedotin for recurrent/metastatic nasopharyngeal carcinoma (Magic-M001): a multicenter, randomized trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: March 20, 2026
Structure-specific involvement in advanced cervical lymph node extranodal extension predicts prognosis in nasopharyngeal carcinoma: A multi-center study.
Journal: Oral oncology
Published: March 17, 2026
First-Line Tislelizumab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer: Three-Year Follow-Up of the Phase 3 RATIONALE-309 Randomized Clinical Trial.
Journal: JAMA oncology
Published: February 26, 2026
Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial.
Journal: JAMA oncology
Published: January 29, 2026
Recombinant Human Thrombopoietin Combined With Avatrombopag for Chemoradiotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma: A Prospective, Randomized Controlled Trial.
Journal: British journal of hospital medicine (London, England : 2005)
Published: September 25, 2025
Expert consensus on the combination of Anti-EGFR monoclonal antibodies and immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma.
Journal: Cancer treatment reviews
Published: September 08, 2025
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.
Journal: Lancet (London, England)
Published: September 08, 2025
Anti-PD-1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double-blind phase 3 study.
Journal: Signal transduction and targeted therapy
Published: August 12, 2025
Last Updated: 09/26/2026